Provided by Tiger Trade Technology Pte. Ltd.

Eton Pharmaceuticals, Inc.

16.26
-0.5500-3.27%
Post-market: 16.260.00000.00%17:01 EST
Volume:197.51K
Turnover:3.26M
Market Cap:436.05M
PE:-62.83
High:16.86
Open:16.70
Low:16.24
Close:16.81
52wk High:23.00
52wk Low:11.09
Shares:26.82M
Float Shares:18.14M
Volume Ratio:0.70
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2588
EPS(LYR):-0.1476
ROE:-34.17%
ROA:1.25%
PB:18.86
PE(LYR):-110.14

Loading ...

Eton Pharmaceuticals Issues Amended Financial Report on Acquired Increlex Product

Reuters
·
Nov 19

Eton Pharmaceuticals Q3 2025 Earnings Call Summary and Q&A Highlights: Record Revenue Growth and Strategic Expansion

Earnings Call
·
Nov 09

Eton Pharma (ETON) Q3 2025 Earnings Transcript

Motley Fool Transcribing
·
Nov 09

Eton Pharmaceuticals Q3 Adj. EPS $0.04 Misses $0.09 Estimate, Sales $22.459M Beat $20.474M Estimate

Benzinga
·
Nov 07

BRIEF-Eton Pharmaceuticals Q3 Net Income USD -1.927 Million

Reuters
·
Nov 07

Eton Pharmaceuticals Q3 Adjusted EPS USD 0.04

THOMSON REUTERS
·
Nov 07

Eton Pharmaceuticals Q3 EPS USD -0.07

THOMSON REUTERS
·
Nov 07

3 Growth Companies With Insider Ownership Up To 31%

Simply Wall St.
·
Oct 30

CFO James R. Gruber Reports Disposal of Common Shares of Eton Pharmaceuticals Inc

Reuters
·
Aug 21

Eton Pharmaceuticals Q2 Net Income USD -2.585 Million

Reuters
·
Aug 08

Eton Pharmaceuticals Q2 Adj. EPS $(0.10) Misses $(0.05) Estimate, Sales $18.93M Beat $16.60M Estimate

Benzinga
·
Aug 08

Eton Pharmaceuticals Inc - Projects $80 Mln Annual Revenue Run Rate in Q3

THOMSON REUTERS
·
Aug 08

Eton Pharmaceuticals Inc Q2 REV View $16.7 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Aug 08

Eton Pharmaceuticals Q2 Revenue USD 18.9 Million

THOMSON REUTERS
·
Aug 08

Eton Pharmaceuticals Inc expected to post a loss of 4 cents a share - Earnings Preview

Reuters
·
Aug 06

REFILE-BUZZ-U.S. STOCKS ON THE MOVE-BTCS, BrainStorm Cell, Moderna

Reuters
·
Jul 09

BUZZ-U.S. STOCKS ON THE MOVE-ProKidney, Eton Pharma, Datadog

Reuters
·
Jul 08

BUZZ-Eton Pharma rises after US FDA accepts application for hormone disorder drug

Reuters
·
Jul 08

BRIEF-Eton Pharmaceuticals Announces FDA Acceptance Of New Drug Application For Et-600

Reuters
·
Jul 08

Eton Pharmaceuticals Announces FDA Acceptance of NDA for ET-600 Desmopressin Oral Solution, Target Action Date Set for February 25, 2026

Reuters
·
Jul 08